Clinical Trials
19
Active:0
Completed:4
Trial Phases
5 Phases
Early Phase 1:1
Phase 2:1
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)β’ Click on a phase to view related trials
Phase 4
6 (50.0%)Not Applicable
2 (16.7%)Phase 3
2 (16.7%)Early Phase 1
1 (8.3%)Phase 2
1 (8.3%)Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
Not Applicable
Not yet recruiting
- Conditions
- Colorectal AdenomaHigh RiskTCM
- Interventions
- Drug: Shenbai GranulesDrug: Placebo
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT07129499
- Locations
- π¨π³
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas
Not Applicable
Not yet recruiting
- Conditions
- Colorectal AdenomaTCMLow Risk
- Interventions
- Drug: Shenbai GranulesDrug: Placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT07123116
- Locations
- π¨π³
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06613373
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
Not yet recruiting
- Conditions
- HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06537674
Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
Not yet recruiting
- Conditions
- Colorectal CancerColorectal Adenoma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 50000
- Registration Number
- NCT06136026
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found